| PRLog Free Press Release | + Bookmark This Page |
Filter News Show All ResultsShow Filtered Results Category - Games (x)Country - Thailand (x)State / Province (To see all states,remove category filter) City / Town Select State First | AlliedPath Announces New SAB Members
FOR IMMEDIATE RELEASE
PR Log (Press Release) –
Oct 22, 2009 – SAN DIEGO — AlliedPath, a state of the art clinical laboratory specializing in solid tumor cancer- molecular diagnostics, announced today the appointment of Richard C. Friedberg, MD, PhD, and Eric Topol, MD to their Scientific Advisory Board.
Richard C. Friedberg, MD, PhD is Chairman of the Department of Pathology for Baystate Health in Springfield, Massachusetts. He is also Professor and Deputy Chairman of the Department of Pathology, Tufts University School of Medicine in Boston, Massachusetts. Dr. Friedberg holds a BS from Stanford University, a PhD and MD from Duke University, and a Masters in Health Care Management from Harvard University. He is a fellow of the College of American Pathologists (CAP) and a member of the Board of Governors. He is also a member of the CAP Council of Government and Professional Affairs, as well as the Strategic Planning, Technology Assessment, and Finance Committees. Eric Topol, MD is Director, Scripps Translational Science Institute and Professor of Translational Genomics, Department of Molecular and Experimental Medicine at The Scripps Research Institute. He is also the Founding Dean, Scripps School of Medicine and Chief Academic Officer, Scripps Health. Dr. Topol holds a BA from the University of Virginia and MD from University of Rochester, is a Tenured Professor at the University of Michigan, and Founder of the Cleveland Clinic Lerner College of Medicine. “Dr. Friedberg and Dr. Topol’s wealth of knowledge and expertise is pivotal to our goal of delivering timely diagnostic services in the fight against cancer.” said Dr. Philip Ginsburg, AlliedPath’s CEO. Dr. Ginsburg also stated “AlliedPath will continue to add thought leaders to our scientific advisory board to ensure we remain in the forefront of molecular solid tumor cancer testing.” # # # AlliedPath, Inc. is a leading cancer-focused molecular diagnostics testing laboratory which offers an extensive menu of high-quality, solid tumor specific tests. We partner with regional hospital and reference laboratories to provide test results which are combined with expert pathology analysis into an easy to interpret patient report for the oncologist. The results provide relevant information for the physician to determine optimal treatment strategies, improving personalized medical care and enhancing quality of life for the patient. Additionally, AlliedPath will serve the pharmaceutical industry by providing specialized molecular tests that are integral tools for predicting drug safety and efficacy. To embed this press release, copy and paste the following HTML code into your webpage-
Email to a Friend Previous News Next News
Disclaimer: Issuers of the press releases are solely responsible for the content of their press releases. PRLog.Org can't be held liable for the contents of the press releases. Report Abuse Upcoming Press Releases...
| For Businesses ...
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||